Skip to main content
. 2021 Jun 16;11:665484. doi: 10.3389/fonc.2021.665484

Figure 2.

Figure 2

(A) Comparison of PFS of first-generation EGFR TKIs for patients with EGFR mutations alone and patients harboring both EGFR mutations and other potentially actionable oncogenic drivers. (B) PFS of first-generation EGFR TKIs for EGFR-mutant patients with concurrent MET amplification, ERBB2 amplification, and other oncogenic drivers.